Therefore targeting interventions of these pathways, suchas EZH2 inhibitors, Sirt1 activators, and Nedd4-2 modulators, will be the subjectof future studies in an attempt to develop new therapeutic strategies for thetreatment of arrhythmias in clinical practice. This evidence concerns the gene SIRT1 and cardiac arrhythmia.